Ankyra Medical Journal (AnkMJ), formerly known as the Journal of Translational and Practical Medicine, regularly publishes international quality issues in the field of Medicine in the light of current information.

EndNote Style
Original Article
Laboratory changes and parenchymal changes in computed tomography after COVID-19 pneumonia
Aims: Novel coronavirus-2019 (2019-nCoV) has caused a global pandemic. Fort his reason, our study is to determine the variables of thorax tomography findings and laboratory data after covid 19 pneumonia in cases with severe covid 19 pneumonia and to detect the findings of possible interstitial lung diseases.
Methods: In this single-center study, 61 consecutive patients were examined. These patients were admitted to the COVID-19 Pandemic Clinic of Malatya Training and Research Hospital between July 15, 2020 and August 28, 2020 and were hospitalized with a diagnosis of COVID-19 pneumonia. Patients were discharged after the illness, and after 6 months, they applied to the outpatient clinic for follow-up. In this study, we compared the changes in laboratory variables and thorax CT scans at the time of diagnosis and 6 months later. Patients were divided into groups 1 and 2. Group 1: patients who were diagnosed with COVID 19 pneumonia at initial presentation and had thorax CT and laboratory parameters at the time of diagnosis and group 2: patients who presented to the outpatient clinic for 6-month follow-up during the postcovid pneumonia period and had control thorax CT and laboratory parameters.
Results: When the laboratory parameters of group 1 and group 2 patients were statistically compared. In addition to the increase in glucose, creatinine, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, lactate dehydrogenase, aptt, INR, fibrinogen, neutrophil percentage, mean erythrocyte hemoglobin, albumin, the decrease in calcium, sodium, leukocyte, platelet, hemoglobin, lymphocyte count, erythrocyte distribution range variables were found to be statistically significant (p<0.05). In our study, ground glass opacity was seen most frequently in Group 1 Thorax CT and was found in 57 patients. In 10 of these 57 patients, ground-glass opacity was positive on Group 1 and Group 2 Thorax CT, while ground-glass opacity was negative on Group 2 Thorax CT in 47 patients. In 50 patients, consolidation was found on Group 1 Thorax CT and consolidation was positive on Group 1 and Group 2 Thorax CT in 5 patients. The changes in fibrosis, parenchymal band, reticular opacity, traction bronchiectasis, irregular interfaces, ground glass opacity, consolidation, and pulmonary nodule variables in Group 2 Thorax CT were statistically significant (p<0.05).
Conclusion: Laboratory data is very important in terms of COVID-19 infection diagnosis, prognosis and guiding treatment. It may be due to the fact that patients with residual abnormalities on control thorax CT after COVID-19 pneumonia were older, had more comorbid diseases, and had severe clinical disease at the time of hospitalization.

1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalizedpatients with 2019 novel coronavirus-infected pneumonia in Wuhan,China. JAMA. 2020;323(11):1061-1069.
2. Demirhan R, Cimenoglu B, Yilmaz E. The effects of hospitalorganization on treatment during COVID-19 pandemic. South Clin IstEuras. 2020;31(2):89-95.
3. World Health Organization. Coronavirus disease 2019 (COVID19)Situation Report 28. iruse/situation-repor ts/2020 0217-sitrep-28-cov id19.pdf?sfvrsn=a19cf2ad_2 Accessed March 9, 2022
4. Banu K. Clinical findings of &not; e COVID-19 in the adult group. JBiotechnol Strategic Health Res. 2020;1:85-90.
5. Somsen GA, van Rijn C, Kooij S, Bem RA, Bonn D. Small dropletaerosols in poorly ventilated spaces and SARS-CoV-2 transmission.Lancet Respir Med. 2020;8(7):658-659.
6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortalityof adult inpatients with COVID-19 in Wuhan, China: a retrospectivecohort study. Lancet. 2020;395:1054-1062.
7. Wu Z, McGoogan JM. Characteristics of and important lessons fromthe coronavirus disease 2019 (COVID-19) outbreak in China: summaryof a report of 72 314 cases from the Chinese Center for Disease Controland Prevention. JAMA. 2020;323(13):1239-1242.
8. Ufuk F, Savaş R. Chest CT features of the novel coronavirusdisease(COVID-19). Turk J Med Sci. 2020;50(4):664-678.
9. Ak&ccedil;ay S, &Ouml;zl&uuml; T, Yılmaz A. Radiological approaches to COVID-19pneumonia. Turk J Med Sci. 2020;50(9):604-610.
10. Alhazzani W, Evans L, Alshamsi F, et al. Surviving sepsis campaignguidelines on the management of adults with coronavirus disease 2019(COVID-19) in the ICU: first update. Crit Care Med. 2021;49(3):e219-e234.
11. Franquet T. Imaging of pulmonary viral pneumonia. Radiol.2011;260(1):18-39.
12. Koo HJ, Lim S, Choe J, Choi SH, Sung H, Do KH. Radiographic and CTfeatures of viral pneumonia. Radiograph. 2018;38(3):719-739.
13. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL,Remy J. Fleischner Society: glossary of terms for thoracic imaging.Radiol. 2008;246(3):697-722.
14. Pan F, Ye T, Sun P, et al. Time course of lung changes on chest CTduring recovery from 2019 novel coronavirus (COVID-19) pneumonia.Radiol. 2020;295(3):715-721.
15. Meeting the challenge of long COVID (editorial). Nat Med.2020;26(12):1803.
16. Brodin P. Immune determinants of COVID-19 disease presentationand severity. Nat Med. 2021;27(1):28-33.
17. Brenner DR, Scherer D, Muir K, et al. A review of the application ofinflammatory biomarkers in epidemiologic cancer research. CancerEpidemiol Biomarkers Prev. 2014;23(9):1729-1751.
18. Wang T, Du Z, Fengxue Zhu, et al. Comorbidities and multi-organinjuries in the treatment of COVID-19. Lancet. 2020;395(10228):e52.
19. T&uuml;lay &Uuml;U , Mesut D , Heval CB. Diagnostic utility and prognostic valueof basic laboratory parameters in COVID-19. Klimik J. 2021;34(3):174-181.
20. Liu D, Zhang W, Pan F, et al. The pulmonary sequalae in dischargedpatients with COVID- 19: a short-term observational study. Respir Res.2020;21(1):125.
21. Zhao YM, Shang YM, Song WB, et al. Follow-up study of thepulmonary function and related physiological characteristics ofCOVID-19 survivors three months after recovery. EClinicalMedicine.2020;25:100463.
22. Barisione E, Grillo F, Bal L, et al. Fibrotic progression and radiologiccorrelation inmatched lung samples from COVID-19 post-mortems.Virchows Arch. 2020;478(3):471-485.
23. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findingsin a series of COVID-19 cases from northern Italy: a two-centredescriptive study. Lancet Infect Dis. 2020;20(10):1135-1140.
24. Gentile F, Aimo A, Forfori F, et al. COVID-19 and risk of pulmonaryfibrosis: the importance of planning ahead. Eur J Preven Cardiol.2020;27(13):1442-1446.
25. Huang W,Wu Q, Chen Z, et al. The potential indicators for pulmonaryfibrosis in survivors of severe COVID-19. J Infect. 2021;82(2):e5-e7.
26. Kucuk C,Turkkani MH, Arda K. A case report of reversiblebronchiectasis in an adult: pseudobronchiectasis. Respir Med Case Rep.2019;26:315-316.
27. Lechowicz K, Drozdzal S, Machaj F, et al. COVID-19: The potentialtreatment of pulmonary fibrosis associated with SARS-CoV-2 infection.J Clin Med. 2020;9(6):1917.
28. Hu T, Liu Y, Zhao M, et al. A comparison of COVID-19, SARS andMERS. Peer J. 2020;8:e9725.
29. Shaw B, Daskareh M, Gholamrezanezhad A. The lingeringmanifestations of COVID-19 during and after convalescence: updateon long-term pulmonary consequences of coronavirus disease 2019(COVID-19). Radiol Med. 2020;126(1);40-46.
Volume 3, Issue 2, 2024
Page : 33-40